Is there a risk of immune-mediated cardiotoxicity in patients with metastatic NSCLC and malignant pericarditis treated with checkpoint inhibitors?
Would the presence of malignant pericarditis influence your decision for first line therapy between immunotherapy vs chemotherapy?